Another thought: if pbt2 and whatever the outliers in the placebo group were doing reduced brain atrophy and increased the clearance of amyloid (especially oligomers), but did not appear to improve memory would the combination of the two produced better results in terms of cognitive function? Maybe there is a hint of this in the previous trial results:
J Alzheimers Dis. 2010;20(2):509-16. doi: 10.3233/JAD-2010-1390.
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses.
Faux NG1, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE,Cummings JL, Herd CM, Bush AI.
Author information
Abstract
PBT2 is a copper/zinc ionophore that rapidly restores cognition in mouse models of Alzheimer's disease (AD). A recent Phase IIa double-blind, randomized, placebo-controlled trial found that the 250 mg dose of PBT2 was well-tolerated, significantly lowered cerebrospinal fluid (CSF) levels of amyloid-beta42, and significantly improved executive function on a Neuro-psychological Test Battery (NTB) within 12 weeks of treatment in patients with AD. In the post-hoc analysis reported here, the cognitive, blood marker, and CSF neurochemistry outcomes from the trial were subjected to further analysis. Ranking the responses to treatment after 12 weeks with placebo, PBT2 50 mg, and PBT2 250 mg revealed that the proportions of patients showing improvement on NTB Composite or Executive Factor z-scores were significantly greater in the PBT2 250 mg group than in the placebo group. Receiver-operator characteristic analyses revealed that the probability of an improver at any level coming from the PBT2 250 mg group was significantly greater, compared to placebo, for Composite z-scores (Area Under the Curve [AUC] =0.76, p=0.0007), Executive Factor z-scores (AUC =0.93, p=1.3 x 10(-9)), and near-significant for the ADAS-cog (AUC =0.72, p=0.056). There were no correlations between changes in CSF amyloid-beta or tau species and cognitive changes. These findings further encourage larger-scale testing of PBT2 for AD.
- Forums
- ASX - By Stock
- ATH
- I don't know! Maybe...
ATH
alterity therapeutics limited
Add to My Watchlist
11.1%
!
1.0¢

I don't know! Maybe..., page-5
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.001(11.1%) |
Mkt cap ! $91.27M |
Open | High | Low | Value | Volume |
1.0¢ | 1.0¢ | 0.9¢ | $9.419K | 1.001M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 63876237 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 4097409 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 63821237 | 0.009 |
20 | 10741186 | 0.008 |
18 | 11127963 | 0.007 |
12 | 7003518 | 0.006 |
6 | 3460001 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 1507201 | 7 |
0.011 | 8119746 | 22 |
0.012 | 13507542 | 22 |
0.013 | 6265068 | 10 |
0.014 | 12788180 | 6 |
Last trade - 16.15pm 04/07/2025 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online